ABOUT AJPP

The African Journal of Pharmacy and Pharmacology (AJPP) is published weekly (one volume per year) by Academic Journals.

African Journal of Pharmacy and Pharmacology (AJPP) is an open access journal that provides rapid publication (weekly) of articles in all areas of Pharmaceutical Science such as Pharmaceutical Microbiology, Pharmaceutical Raw Material Science, Formulations, Molecular modeling, Health sector Reforms, Drug Delivery, Pharmacokinetics and Pharmacodynamics, Pharmacognosy, Social and Administrative Pharmacy, Pharmaceutics and Pharmaceutical Microbiology, Herbal Medicines research, Pharmaceutical Raw Materials development/utilization, Novel drug delivery systems, Polymer/Cosmetic Science, Food/Drug Interaction, Herbal drugs evaluation, Physical Pharmaceutics, Medication management, Cosmetic Science, pharmaceuticals, pharmacology, pharmaceutical research etc. The Journal welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published shortly after acceptance. All articles published in AJPP are peer-reviewed.

Submission of Manuscript

Submit manuscripts as e-mail attachment to the Editorial Office at: ajpp@academicjournals.org. A manuscript number will be mailed to the corresponding author shortly after submission.

The African Journal of Pharmacy and Pharmacology will only accept manuscripts submitted as e-mail attachments.

Please read the Instructions for Authors before submitting your manuscript. The manuscript files should be given the last name of the first author.
Editors

Sharmilah Pamela Seetulsingh-Goorah
Associate Professor,
Department of Health Sciences
Faculty of Science,
University of Mauritius,
Reduit,
Mauritius

Dr. B. RAVISHANKAR
Director and Professor of Experimental Medicine
SDM Centre for Ayurveda and Allied Sciences,
SDM College of Ayurveda Campus,
Kuthpady, Udupi-574118
Karnataka (INDIA)

Himanshu Gupta
University of Colorado-Anschutz Medical Campus,
Department of Pharmaceutical Sciences, School of
Pharmacy Aurora, CO 80045,
USA

Dr. Manal Moustafa Zaki
Department of Veterinary Hygiene and Management
Faculty of Veterinary Medicine, Cairo University
Giza, 11221 Egypt

Dr. Shreesh Kumar Ojha
Molecular Cardiovascular Research Program
College of Medicine
Arizona Health Sciences Center
University of Arizona
Tucson 85719, Arizona,
USA

Prof. George G. Nomikos
Scientific Medical Director
Clinical Science
Neuroscience
TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC. 675 North Field Drive Lake Forest, IL 60045
USA

Dr. Victor Valenti Engracia
Department of Speech-Language and
Hearing Therapy Faculty of Philosophy
and Sciences, UNESP
Marilia-SP, Brazil

Prof. Mahmoud Mohamed El-Mas
Department of Pharmacology,

Dr. Sutiak Vaclav
Rovníková 7, 040 20 Košice,
The Slovak Republic,
The Central Europe,
European Union
Slovak Republic
Slovakia

Prof. Caroline Wagner
Universidade Federal do Pampa
Avenida Pedro Anunciação, s/n
Vila Batista, Caçapava do Sul, RS - Brazil

Dr. Caroline Wagner
Universidade Federal do Pampa
Avenida Pedro Anunciação, s/n
Vila Batista, Caçapava do Sul, RS - Brazil

Dr. Victor Valenti Engracia
Department of Speech-Language and
Hearing Therapy Faculty of Philosophy
and Sciences, UNESP
Marilia-SP, Brazil

Prof. Mahmoud Mohamed El-Mas
Department of Pharmacology,
# Editorial Board

**Prof. Fen Jicai**  
*School of life science, Xinjiang University, China.*

**Dr. Ana Laura Nicoletti Carvalho**  
*Av. Dr. Arnaldo, 455, São Paulo, SP, Brazil.*

**Dr. Ming-hui Zhao**  
*Professor of Medicine  
Director of Renal Division, Department of Medicine  
Peking University First Hospital  
Beijing 100034  
PR. China.*

**Prof. Ji Junjun**  
*Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, China.*

**Prof. Yan Zhang**  
*Faculty of Engineering and Applied Science, Memorial University of Newfoundland, Canada.*

**Dr. Naoufel Madani**  
*Medical Intensive Care Unit  
University hospital Ibn Sina, University Mohamed V Souissi, Rabat, Morocco.*

**Dr. Dong Hui**  
*Department of Gynaecology and Obstetrics, the 1st hospital, NanFang University, China.*

**Prof. Ma Hui**  
*School of Medicine, Lanzhou University, China.*

**Prof. Gu Huijun**  
*School of Medicine, Taizhou university, China.*

**Dr. Chan Kim Wei**  
*Research Officer  
Laboratory of Molecular Biomedicine, Institute of Bioscience, Universiti Putra, Malaysia.*

**Dr. Fen Cun**  
*Professor, Department of Pharmacology, Xinjiang University, China.*

**Dr. Sirajunnisa Razack**  
*Department of Chemical Engineering, Annamalai University, Annamalai Nagar, Tamilnadu, India.*

**Prof. Ehab S. EL Desoky**  
*Professor of pharmacology, Faculty of Medicine  
Assiut University, Assiut, Egypt.*

**Dr. Yakisich, J. Sebastian**  
*Assistant Professor, Department of Clinical Neuroscience  
Memorial University of Newfoundland, Canada.*

**Prof. Dr. Andrei N. Tchernitchin**  
*Head, Laboratory of Experimental Endocrinology and Environmental Pathology LEEPA  
University of Chile Medical School, Chile.*

**Dr. Sirajunnisa Razack**  
*Department of Chemical Engineering, Annamalai University, Annamalai Nagar, Tamilnadu, India.*

**Dr. Yasar Tatar**  
*Marmara University, Turkey.*

**Dr Nafisa Hassan Ali**  
*Assistant Professor, Dow institute of medical technology  
Dow University of Health Sciences,Chand bbi Road, Karachi, Pakistan.*

**Dr. Krishnan Namboori P. K.**  
*Computational Chemistry Group, Computational Engineering and Networking, Amrita Vishwa Vidyapeetham, Amritanagar, Coimbatore-641 112  
India.*

**Prof. Osman Ghani**  
*University of Sargodha, Pakistan.*

**Dr. Liu Xiaoji**  
*School of Medicine, Shihezi University, China.*
<table>
<thead>
<tr>
<th>ARTICLES</th>
</tr>
</thead>
</table>

**Research Articles**

**Protective Action Of Taraxacum Officinale On CCl₄ Induced Hepatotoxicity In Rats**  
Dawood Ahmad, Muhammad Gulfraz, M. Sheeraz Ahmad, Habiba Nazir, Hina Gul and Saira Asif  
775

**Study Of Visceral Antinociceptive Potential Of Bee Apis Mellifera Venom**  
Meizhu Zheng, Yuqiu Li, Dongfang Shi, Chunming Liu and Jimin Zhao  
781
Full length research paper

Protective action of *Taraxacum officinale* on CCl₄ induced hepatotoxicity in rats

Dawood Ahmad¹, Muhammad Gulfraz¹*, M. Sheeraz Ahmad¹, Habiba Nazir¹, Hina Gul² and Saira Asif³

¹UIBB, PMAS Arid Agriculture University Rawalpindi, Pakistan.
²Department of Plant sciences Quaid -I- Azam University, Islamabad, Pakistan.
³Department of Botany, PMAS Arid Agriculture University Rawalpindi, Pakistan.

Received 23 May, 2013; Accepted 5 July, 2014

Plants are important source of medicines, especially in developing countries, where people use plant based traditional medicines for their health care. Leaves of *Taraxacum officinale* L. are being used against various human disorders in folk medicine since past. Current study was conducted to explore the hepatoprotective activity of methanolic leaves extract of *T. officinale* L. against carbon tetrachloride (CCl₄) induced toxicity in rats. Various concentrations of plant extracts like 150 and 300 mg/kg of body weight as well as silymarin (100 mg/kg), a standard drug, was given to experimental animals. The results of this study indicates that the methanolic leave extracts has significantly reduced (P < 0.05) the level of liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) which was increased due to induction of CCl₄. It was also observed that due to CCl₄ induction, the level of bilirubin, lipid profile and antioxidants enzymes was also increased, that was significantly lowered after the treatment with the leave extracts. These results revealed that the leave extracts of *T. officinale* L. has protective effects against CCl₄ induced liver toxicity and damage. Furthermore, histopathtological results obtained during this study also supported this claim and was probably due to presence of valuable phytochemicals in the leave extracts.

**Key words:** Medicinal plants, *Taraxacum officinale*, leaves extract, animals, liver enzymes.

INTRODUCTION

Liver is a vital organ which plays a major role in different metabolisms and excretion of xenobiotics from the body. Liver dysfunction is a major health problem which is a challenge not only for health care professionals but also for the pharmaceutical industry and drug regulatory agencies. Liver cell injuries are caused by various toxic chemicals such as antibiotics, chemotherapeutic agents, carbon tetrachloride etc (Allies, 1990; Sing and Rao, 2008). Liver cells are also damaged due to excessive alcohol consumption and microbial action (Ahmed et al., 1987). The available synthetic drugs to treat liver disorders are also causing further damage to the liver (Singh and Rao, 2008). Furthermore, in the recent past, it was observed that the dosage of drugs might be adversely affecting the liver tissues. Many plasma proteins are synthesized in the liver and their plasma...
levels therefore depend on the balance between synthesis and catabolism and/or loss from the body (Edet et al., 2011; Ismail et al., 2010).

The liver enzymes and proteins are important biomarkers in the body utilized in the diagnosis and assessment of normal function of liver. Major or minor changes in the integrity of cellular membranes in tissues or organs have culminated changes in enzyme activities. For instance alanine amino transferase (ALT) and aspartate aminotransferase (AST) are useful in detecting alterations in liver disease while ALT and some other parameters are implicated in extra hepatic or intra-hepatic obstruction (Chatterjea and Shinde, 2002; Singh and Rao, 2008; Edet et al., 2011). In recent years, due to inadequacy of liver protective agents, researchers and traditional medicine practitioners concentrated on herbal based remedies for various liver disorders (Chatterjee, 2000). Many folk remedies from plant sources are available for the protection of hepatic damages starting from ancient period. Medicinal plants possess valuable bioactive compounds that protects human from various complications. World Health Organization estimated that about 80% population in Africa and majority of population in Asia and Latin America still use traditional medicines for their primary health care. Phytotherapy play vital role in detoxification of oxidative stress and other degenerative disorder with minimum or no side effects comparatively to other types of drugs (Reilly and Bulkley, 1990).

*T. officinalis* (Asteraceae) locally known as Dandelion has been commonly used by rural people against many human disorders including liver and kidney diseases (Dirlesi et al., 2012; You et al., 2010; Agarwal, 2001). The present work was conducted to prove scientifically hepatoprotective activity of *T. officinalis* in rats.

**MATERIALS AND METHODS**

**Plant and chemicals**

Carbon tetrachloride (CCl₄) was purchased from Aldrich Chemical Co. All other chemicals used in this study were of analytical grade and products of May and Baker, England; BDH, England and Merck, Darmstadt, Germany. Reagents used for all the assays were commercial kits and products of Randox, USA. Fresh leaves of *T. officinalis* L. were collected in April, 2010 from different locations of Rawalpindi areas. The samples were identified and authenticated by a taxonomist and registered as a specimen (voucher specimen numbers 217).

**Preparation of plant samples**

The leaves were air-dried for 2 weeks and then ground into fine powder using an electric dry mill. A total of 200 g of the ground powder was soaked in 1 L of distilled water for 48 h at room temperature. The mixture was filtered into 500 ml conical flask with Whatman filter paper (No.1). The filtrate was dried at a temperature of 30°C for 10 h to produce a extract, which weighed 20.0 g. Appropriate concentration of the extract was then subsequently made by dilution with methanol into 150 and 300 mg/kg/body weight and administered to the animals.

**Phytochemical analysis**

Preliminary phytochemical tests were carried out on the methanol extract of the leaves using standard methods (Harbone, 1973; Trease and Evans, 1983).

**Animals**

Twenty five (25) male albino rats of Wistar strain were used in this study. The rats having weight of 100 to 150 g were maintained under standard animal house conditions and were fed with commercial rat chow (Feed Mills, Islamabad) and allowed water *ad libitum*. Animals were divided into 5 groups having 5 animals in each group and maintained in standard lab conditions with 12-hours cycle of light and dark. Room temperature was kept at 22 ± 2°C and humidity was maintained at 50 ± 5%. The protocol was approved by animal ethics committee of the University.

**Acute toxicity tests**

The acute toxicity tests were carried out by following a method reported by Lorke (1983). The extract was found to be relatively safe. Doses of 150 and 300 mg/kg of extracts were then chosen and administered to the rats.

**Hepatoprotective activity**

A total of 25 animals were divided into 5 groups of 5 animals in each group (n = 5). Group I (control) received olive oil orally for 14 days. Group II (hepatotoxin control) received a single dose of 5 ml/kg of CCl₄ diluted in olive oil, 1:1 ratio for 14 days alternatively. Group III (Test group 1) were administered with single dose of 5 ml/kg of CCl₄ along with vehicle alternatively for 14 days and it was followed by the treatment with 150 mg/kg of *T. officinalis* leaves extract orally for 21 days. Group IV (Test group 2) animals were administered with single dose of 5 ml/kg of CCl₄ for 14 days, followed by treatment with 300 mg/kg of *T. officinalis* leaves extract for 21 days. Group IV (hepatoprotective agent control) animals were administered with CCl₄ for 14 days and followed by the treatment with 100 mg/kg of known hepatoprotective agent (silymarin). On 22nd day, the animals were anaesthetized using chloroform and blood was collected by cardiac puncture.

**Preparation of serum**

Blood was obtained from the rats by heart puncture technique into centrifuge tubes. Serum was prepared by centrifugation for 10 min at 3000 rev/h in a bench centrifuge. The clear supernatant was used for the biochemical tests.

**Biochemical analysis**

Liver enzymes such as AST, ALT, ALP and lipid profile - total cholesterol, very low density lipoprotein (VLDL), high density lipoprotein (HDL), triglycerides were estimated by using commercially available kits based on the methods reported by Reitman and Frankel (1957), King and Kind (1954). Whereas, bilirubin was determined by using method reported by Jendrassac and Grof (1938). The activities of anti oxidants enzymes such as superoxide dismutase (SOD), catalase and glutathione peroxidase
Table 1. Phytochemical analysis of leaf extracts of *T. officinalis*.

<table>
<thead>
<tr>
<th>Constituent</th>
<th>Relative abundance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyphenols</td>
<td>++</td>
</tr>
<tr>
<td>Flavonoids</td>
<td>++</td>
</tr>
<tr>
<td>Alkaloids</td>
<td>++</td>
</tr>
<tr>
<td>Glycosides</td>
<td>+</td>
</tr>
<tr>
<td>Reducing sugar</td>
<td>++</td>
</tr>
<tr>
<td>Saponins</td>
<td>+</td>
</tr>
<tr>
<td>Tannins</td>
<td>+</td>
</tr>
</tbody>
</table>

++ = Highly present, + = Present

(GPx) were assayed in the hepatic tissue of control and experimental group of animals by using methods reported by Kakkar et al. (1984), Sinha (1972) and Rotruck et al. (1973), respectively. Whereas, the level of lipid peroxide-malondialdehyde (MDA) was also determined by using serum, as well as liver tissue of control and experimental groups of animals (Berton et al., 1998).

**Histopathological studies**

The liver tissues were subjected to normal routine histological procedures, stained with hematoxylin-eosin and examined using the light microscope for any morphological changes (Kleiner et al., 2005).

**Statistical analysis**

Data obtained was analyzed by one way analysis of variance (ANOVA), followed by Bonferoni test for comparison by using SPSS software version 16.0, and the P < 0.05 was considered as statistically significant.

**RESULTS**

The preliminary screening of phytochemicals from leaf samples of *T. officinalis* revealed the presence of polyphenols, alkaloids, flavonoids, glycosides, reducing sugar, saponins and tannins. Results indicate that proportion of polyphenols, flavonoids and alkaloids found in the extract was relatively higher than the other phytochemicals (Table 1). Methanolic leaf extracts of *T. officinalis* (150 and 300 mg/kg bw) when given orally for 21 days showed hepatoprotective activity in CCl4 induced hepatic damage in rats. Results show increases in the liver enzymes like ALT, AST, ALP and bilirubin in CCl4 intoxicated animals when compared with that of the control group of rats (Table 2). Treatment of CCl4 induced animals with different concentrations of plant extracts (150 and 300 mg/kg) significantly reduced (P < 0.05) CCl4 induced elevations in enzymes on dose dependent manner as compared to control. The recovery of hepatic injury was observed in animals treated with plant extracts as well as with silymarin. Hepatic injury caused by CCl4 administration at a dose of 5 ml/kg body weight showed significant increase in the lipid profile (total cholesterol, triglycerides, LDL and VLDL) levels in liver tissues. Whereas HDL level was decreased as compared to that of control group of rats (p < 0.05). However, the treatment of CCl4 induced group of rats with extracts of *T. officinalis* at a dose of 150 and 300 mg/kg and also, a known hepatoprotective agent silymarin (100 mg/kg), showed significant reduction in level of liver cholesterol, triglyceride, VLDL and LDL, whereas HDL level was increased as compared to CCl4 treated group (Table 3).

The effects of methanolic leaves extracts of *T. officinalis* on the antioxidants enzymes like catalase, GPx and SOD in the serum of control and CCl4 treated group showed significant reduction (p < 0.05). The methanolic leaves extracts of *T. officinalis* and silymarin increased the revised activities of these antioxidants in the liver of CCl4 induced group on dose dependent manner as compared to control and the change was significant (p < 0.05). These results suggested that the free radicals released in the liver were effectively scavenged in the animals treated with *T. officinalis*. Malondialdehyde (MDA) content in liver of CCl4 treated group was significantly higher than that of the control group. However, MDA levels were significantly lowered in CCl4 treated group followed by treatment with methanolic leaves extracts of *T. officinalis* and silymarin (p < 0.05) (Table 4).

The results of histopathological study of the liver tissues of the control and CCl4 treated rats are given in Figures 1 to 4, respectively. The liver section of the animal in control group showed normal hepatic cells, well defined cytoplasm prominent nucleus, nucleolus and a central vein with prominent small-sized (Figure 1). While liver section of CCl4 induced animal showed total loss of hepatic architecture with centrilobur hepatic necrosis, fatty changes vacuolization and congestion of sinusoids (Figure 2). However, treatment of animals with 300 mg/kg of methanolic leaves extracts of *T. officinalis* (Figure 3) and 100 mg/g of silymarin (Figure 4) represent normal condition of liver tissues and it is assumed that treatment returned that injury towards normal side. Therefore, results of histopathological study also provided support for biochemical analysis carried out during this work.

**DISCCUSION**

Carbon tetrachloride (CCl4) is assumed to initiate the biochemical processes leading to oxidative stress, which is the direct cause of many pathological changes in liver, kidney, testes, lungs, nervous system and blood tissues by producing free radicals (Abraham et al., 1999; ATSDR, 2003). These free radicals frequently damage different cell organelles through lipid peroxidation (Ahmed et al., 1987). For example, the acute exposure of CCl4 to the liver tissues can cause damage of liver and lead to elevated levels of its enzymes (Sing and Rao, 2008; Okonkwo et al., 2004). These liver enzymes can then be
Table 2. Effect of methanolic extracts of *T. officinalis* leaves on liver enzyme and bilirubin.

<table>
<thead>
<tr>
<th>Group</th>
<th>AST (U/L)</th>
<th>ALT (U/L)</th>
<th>ALP (U/L)</th>
<th>Total bilirubin (mg/dl)</th>
<th>Direct bilirubin (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>72.4±0.24</td>
<td>38.1±0.21</td>
<td>114.21±0.42</td>
<td>0.15±0.07</td>
<td>1.73±0.07</td>
</tr>
<tr>
<td>CCl4</td>
<td>217.43±0.23a</td>
<td>115.17±0.93a</td>
<td>224.93±0.54a</td>
<td>0.39±0.01a</td>
<td>2.17±0.05a</td>
</tr>
<tr>
<td>CCl4+150 mg/kg extract</td>
<td>155±0.27</td>
<td>88±0.61</td>
<td>173.38±0.19</td>
<td>0.31±0.03</td>
<td>1.94±0.04</td>
</tr>
<tr>
<td>CCl4+300 mg/kg extract</td>
<td>72.6±0.24b</td>
<td>35.15±0.27b</td>
<td>123.73±1.71b</td>
<td>0.24±0.06b</td>
<td>1.79±0.04b</td>
</tr>
<tr>
<td>CCl4+Silymarin (100 mg/kg)</td>
<td>149.81±1.53b</td>
<td>88±0.47</td>
<td>138.83±0.61b</td>
<td>0.25±0.07b</td>
<td>1.83±0.05b</td>
</tr>
</tbody>
</table>

Results were expressed as Mean± SEM (n=5); a P<0.05 compared with control group of rats; b P<0.05 compared with CCl4 induced group of rats.

Table 3. Effect of methanolic extracts of *T. officinalis* leaves on liver lipid profiles.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Cholesterol (mg/dl)</th>
<th>Triglyceride (mg)</th>
<th>HDL (mg/dl)</th>
<th>LDL (mg/dl)</th>
<th>VLDL (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>88.76±0.32</td>
<td>77.35±0.23</td>
<td>29.38±0.35</td>
<td>54.7±0.19</td>
<td>19.41±0.33</td>
</tr>
<tr>
<td>CCl4</td>
<td>132.54±0.19a</td>
<td>135.48±1.18a</td>
<td>23.83±0.34a</td>
<td>98.37±0.23a</td>
<td>27.46±0.16a</td>
</tr>
<tr>
<td>CCl4+150 mg/kg extract</td>
<td>112.29±0.14</td>
<td>97.11±0.24</td>
<td>20.78±0.27</td>
<td>51.38±0.31</td>
<td>13.39±0.18</td>
</tr>
<tr>
<td>CCl4+300 mg/kg extract</td>
<td>84.59±0.26b</td>
<td>75.9±0.25b</td>
<td>21.11±0.17b</td>
<td>62.31±0.24</td>
<td>14.13±0.16b</td>
</tr>
<tr>
<td>CCl4+Silymarin</td>
<td>99.41±0.18b</td>
<td>81.57±0.47</td>
<td>47.83±0.08b</td>
<td>14.13±0.16b</td>
<td>14.13±0.16</td>
</tr>
</tbody>
</table>

Results were expressed as Mean± S.E.M (n=5). a P<0.05 compared with control group of rats. b P<0.05 compared with CCl4 induced group of rats.

Table 4. Effect of Methanolic extracts of *T. Officinalis* leaves on antioxidants enzyme.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Catalase (U/mg of protein)</th>
<th>GPX (U/mg of protein)</th>
<th>SOD (U/mg of protein)</th>
<th>MDA (nm/mg of protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>16.32±0.06</td>
<td>2.65±0.05</td>
<td>46.45±0.04</td>
<td>2.87±0.75</td>
</tr>
<tr>
<td>CCl4</td>
<td>9.74±0.04a</td>
<td>1.64±0.04a</td>
<td>29.5±0.07a</td>
<td>8.83±0.13a</td>
</tr>
<tr>
<td>CCl4+150 mg/kg extract</td>
<td>14.15±0.04</td>
<td>1.98±0.03</td>
<td>42.19±0.03</td>
<td>3.88±0.07</td>
</tr>
<tr>
<td>CCl4+300 mg/kg extract</td>
<td>15.67±0.09b</td>
<td>2.78±0.06b</td>
<td>45.34±0.08b</td>
<td>2.81±0.48b</td>
</tr>
<tr>
<td>CCl4+Silymarin</td>
<td>12.43±0.08b</td>
<td>1.65±0.08b</td>
<td>47.83±0.08b</td>
<td>4.51±0.81b</td>
</tr>
</tbody>
</table>

Catalase (U/mg of protein), glutathione peroxidase (U/mg of protein) superoxide dismutase (U/mg of protein), MDA-nm/mg of protein. Results were expressed as Mean ± SEM (n=5). a P<0.05 compared with control group of rats and b P<0.05 compared with CCl4 induced group of rats.

Figure 1. Liver tissues of normal rat.
bilirubin, total cholesterol LDL, VLDL and triglycerides were also restored towards their normal levels by the treatment of T. officinalis leaves extract. The reason was that the bioactive compounds (phytochemicals) in the extract minimized the adverse effects of CCl₄ by chelating with by-products produced from CCl₄ metabolites. This demonstrates the hepatoprotective role of plant extract which not only involved in considerably decrease in the effect of CCl₄ induced damage but also resulted in the recovery of damaged liver at a significant level (Chungma et al., 2007; You et al., 2010; Dirleise et al., 2012; Sing and Rao, 2008).

Moreover, the previous studies have reported that the oxidative damage to tissues and their cellular components can be prevented by certain antioxidant metabolites present in the plants (Khan and Ahmed, 2009). Therefore, the results obtained from this study clearly indicate that the antioxidant effect of T. officinalis extract resulted in the protection of liver against CCl₄ induced injury (Allis et al., 1990). It was found that the antioxidant activities of enzymes like SOD, GSH-Px and catalase were considerably decreased in the liver in response to CCl₄ administration compared with control group of animals, which indicates the CCl₄ induced oxidative damage of liver (Guven et al., 2003). The level of antioxidant enzymes was significantly improved by administration of 300 mg/kg of leaves extract to CCl₄ intoxicated rats. This further proves that in addition to hepatoprotective affect, T. officinalis has the ability to restore the antioxidant enzyme activities in CCl₄ damaged liver (Kakkar et al., 1984; Sinha, 1972; Rotruck et al., 1973).

From the whole discussion, it is concluded that the current study provides an important platform for the cure of liver damage caused by CCl₄ intoxication in rats. However, more studies are required to prove the availability of lead compounds from T. officinalis leaves extract having hepatoprotective nature.

ACKNOWLEDGMENT

Financial support provided by Institute of Biochemistry and Biotechnology PMAS Arid Agriculture University Rawalpindi for this study is highly appreciated.

REFERENCES


Full Length Research Paper

Study of visceral antinociceptive potential of bee *Apis mellifera* venom

Marcus FB Costa¹, Adriana R Campos², Ana PV Abdon², Renata P Vasconcelos², Carolina A Castro², Marcos H Toyama³, Helena SA Monteiro¹ and Alice MC Martins¹*

¹Universidade Federal do Ceará, Fortaleza, Ceará, Brasil.
²Universidade de Fortaleza, Fortaleza, Ceará, Brasil.
³Unidade São Vicente, Campus do Litoral Paulista, Universidade Estadual Paulista, São Paulo, São Paulo, Brasil.

Received 30 December, 2013; Accepted 16 July, 2014

Pain is one of the most common reasons for patients to seek medical care. Bee *Apis mellifera* venom (AMV) has traditionally been used to treat inflammatory diseases and the alleviation of pain. Herein, we aimed to investigate the visceral antinociceptive potential of *A. mellifera* bee venom and its possible mechanism of action. Acetic acid-induced writhing assay was used in mice to determine the degree of visceral antinociception. Visceral antinociceptive activity was expressed as the reduction in the number of abdominal constrictions. Mice received an intraperitoneal injection of acetic acid after administration of AMV (0.08 or 0.8 mg/kg; intraperitoneally (i.p.)). In mechanistic studies, separate experiments were realized to examine the role of α2-receptors, nitric oxide, calcium channels, K⁺ATP channel activation, TRPV1 and opioid receptors on the visceral antinociceptive effect of AMV (0.8 mg/kg), using appropriate antagonists, yohimbine (2 mg/kg), L-NG-Nitroarginine methyl ester (L-NAME, 10 mg/kg), verapamil (5 mg/kg), glibenclamide (5 mg/kg), ruthenium red (3 mg/kg) or naloxone (2 mg/kg). AMV presented visceral antinociceptive activity in both doses tested (0.08 and 0.8 mg/Kg). Visceral antinociceptive effect of AMV was resistant to all the antagonists used. Mice showed no significant alterations in locomotion frequency, indicating that the observed antinociception is not a consequence of motor abnormality. Although AMV efficient diminished the acetic acid-evoked pain-related behavior, its mechanism is unclear from this study and future studies are needed to verify how the venom exerts its antinociceptive action.

**Key words:** *Apis mellifera* venom, antinociceptive, visceral pain.

INTRODUCTION

Pain is one of the most common reasons for patients to seek medical care. Current analgesics fall into two major classes: non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, both of which have critical liabilities and limitations. Opioids are tightly controlled because of their addictive effects and other serious side effects (McQuay, *Corresponding author. E-mail: martinsalice@gmail.com. Tel: +55 85 33668263. Fax: +55 85 33668292. Author(s) agree that this article remain permanently open access under the terms of the Creative Commons Attribution License 4.0 International License*
Various components of AMV have been identified, but there is not a consensus about their concentration. The predominant component of the dried AMV is melittin (40 to 50%), a peptide of 26 amino acid residues. Moreover, many components with much lower concentration have been identified including hyaluronidase, acid phosphatase, apamin, mast cell degranulating peptide, adolapin, secapin, minimine, phospholipase A2 (PLA2) histamine, glycosidase, tertiapin, dopamine and carbohydrates (Gauldie et al., 1976; Habermann, 1972; Nelson and O’Connor, 1968; Vetter and Visscher, 1998; Vetter et al., 1999). These AMV components were reported to have a wide variety of pharmacological properties (Lariviere and Melzack, 1996).

An animal study suggested that melittin, the main component of whole AMV, is a likely candidate for the anti-inflammatory and antinociceptive effects observed in AMV treatment (Lee et al., 2004). According to Li et al. (2010), the mechanism of the antinociceptive effect of melittin is unknown, but several studies revealed that this effect may be partially explained by the following findings: the repeated application of capsaicin is followed by a prolonged period of hypoalgesia (Nolano et al., 1999); the initial nociceptive effect of melittin may function similarly to capsaicin by increasing the pain thresholds and desensitizing the nociceptor; the α2-adrenoceptor is involved in the anti-nociceptive effect of whole bacterial vaginosis (BV) (Kwon et al., 2001a,b,c); and the antinociceptive effect is dependent on the site-specific acupoint (Oliver et al., 2006).

It was demonstrated that subcutaneous bee venom injection produces a robust antinociceptive effect in several different rodent models of both somatic and visceral pain (Known et al., 2001a,b,c). These preliminary data imply that bee venom is useful for the management of both somatic and visceral pain, but it is not clear which constituent is responsible for its antinociceptive effect. The effects induced by AMV and its components in experimental models of nociceptive and inflammatory pains have been reported (Merlo et al., 2011). These studies demonstrated that AMV antinociception involves the action of different components and does not result from non-specific activation of endogenous antinociceptive mechanisms activated by exposure to noxious stimuli. In the present study, we aimed to investigate the visceral antinociceptive potential of A. mellifera bee venom and its possible mechanism of action.

**MATERIALS AND METHODS**

**Animals**

Swiss mice (20 to 25 g) were used. Experimental groups consisted of 6 animals per group. They were housed at 22 ± 2°C under a 12 h light/12 h dark cycle and had free access to standard pellet diet (Purina chow) and tap water. Each animal was used only once for experimentation. The experimental protocols were in accordance with the ethical guidelines of the Brazilian Council for the Control of Animal Experiments (CONCEA) and were approved by the Animal Research Ethics Committee of the Federal University of Ceará, under entry #90/2011.

**Venom**

The bee AMV was donated by Professor Marcos Hiraki Toyama from Universidade Estadual do Litoral Paulista (UNESP). For the tests, it was prepared a stock solution (1 mg/ml) of the venom in phosphate buffered saline (PBS), pH 7.4, sterile.

**Acetic acid-induced visceral nociception**

Abdominal constrictions were induced by intraperitoneal injection of acetic acid (0.6%). The animals were pretreated with AMV (0.08 or 0.8 mg/kg, intraperitoneally (i.p.)), indomethacin (10 mg/kg, i.p.) or vehicle (PBS 10 ml/kg, i.p.) 30-min prior to acetic acid injection. After the challenge, each mouse was placed in a separate glass funnel and the number of contractions of the abdominal muscles, together with stretching, was cumulatively counted over a period of 20 min. Antinociceptive activity was expressed as the reduction in the number of abdominal contractions, comparing the control animals with the mice pretreated with AMV.

In order to verify the possible involvement of noradrenergic, nitricergic, calcium, K+-ATP, TRPV1, and opioid mechanisms in the effects of AMV, the animals were treated with yohimbine (2 mg/kg, i.p.), L-NAME (10 mg/kg, i.p.), verapamil (5 mg/kg i.p.), ruteinum red (3 mg/kg subcutaneously (s.c.)), glibenclamide (5 mg/kg i.p.) or/and naloxone (2 mg/kg i.p.) 30 min before the administration of the AMV (0.8 mg/kg).

**Evaluation of the motor activity**

The motor coordination and performance of each mouse was evaluated in a rota-rod apparatus, 30 min after the intraperitoneal treatment with AMV (0.08 or 0.8 mg/kg), vehicle (PBS, 10 ml/kg) or Diazepam (1 mg/kg). This apparatus has a 2.5 cm diameter bar, divided into six parts, and it is placed at a height of 25 cm, rotating at 7 rpm. Latency to fall from the rotating bar during a 1 min period was registered.

**Statistical analysis**

The results are presented as the mean ± standard error of mean (SEM) of 8 animals per group. Statistical analysis was carried out using one way analysis of variance (ANOVA) followed by Tukey post hoc test for multiple comparisons. P-values less than 0.05 (p < 0.05) were considered as indicative of statistical significance.

**RESULTS**

In acetic acid-induced writhing test, AMV suppressed the
mean number of writhes, when compared with vehicle-treated control groups (Table 1). These were in the order of 52.17 ± 5.05, 24.67 ± 4.59 and 1.17 ± 0.83, respectively, for the control and AMV at the tested doses of 0.08 and 0.8 mg/kg. The positive control group treated with indomethacin (10 mg/kg, i.p.) also manifested significantly diminished number of stretches (26.00 ± 3.90).

The acetic acid-induced visceral nociception was not significantly blocked by yohimbine, L-NG-Nitroarginine methyl ester (L-NAME), verapamil, ruthenium red, glibenclamide or naloxone. Their combinations with AMV failed to modify AMV antinociception (Table 2).

At the doses tested (0.08 and 0.8 mg/kg), AMV failed to produce any significant effect on motor coordination on rota-rod in mice. In contrast, diazepam (1 mg/kg, i.p.) significantly lowered the motor coordination (data not shown).

**DISCUSSION**

In this present study, it was observed that the acetic acid-evoked visceral nociceptive behavior was significantly attenuated in mice pretreated with AMV. The acetic acid-induced writhing is a standard test for visceral pain, sensitive to opiates as well non-opiates analgesics (Steranka et al., 1987).

The α2-adrenoceptor agonist has been shown to induce antinociceptive effect in the experimental model of formalin-induced colitis in rats and reduce visceral hypersensitivity in clinical settings (Lima-Júnior et al., 2006; Miampamba et al., 1992). Therefore, a possible involvement of α2-adrenoceptors in the antinociceptive effect of AMV, using the antagonist yohimbine was investigated. Yohimbine could not reverse the antinociceptive effect produced by AMV.

Know et al. (2005) reported that a water soluble fraction (BVAF3, <10 kDa) from bee venom selectively activates the descending adrenergic system through α2-adrenergic receptors and that activation is associated with the antinociceptive effect observed in the abdominal visceral pain model. BVAF3 produced a significant antinociceptive effect similar to that observed following injection of AMV. This discrepancy may be due to differences in experimental conditions and the route of AMV delivery.

This study also examined the possible participation of NO/cGMP/K+ATP pathway. Pretreatments with a K+ATP blocker, glibenclamide or the non-specific NOS inhibitor, L-NAME, could not reverse the antinociceptive effect of AMV, suggesting that AMV antinociception do not result from the modulation of K+ATP currents. Besides this, verapamil, blocker of Ca2+ channels, could not reverse the antinociception produced by AMV.

It is currently accepted that an endogenous opioid analgesic system is present at peripheral level (Smith, 2008; Alves et al., 2012), and most of opioid antinociceptive effects are mediated via activation of opioid receptors (Stein and Lang, 2009) and opioid receptors have been identified on peripheral terminals of afferent nerves, which can be the sites of the intrinsic modulation of nociception (Vadivelu et al., 2009). Attempts to mimic or augment such peripheral analgesia may potentially lead to analgesic effects in the absence of the central adverse effects caused by opioids.

The antinociceptive effect of AMV was not modified by a non-selective TRPV1 antagonist ruthenium red. Roh et al. (2010) found that the destruction of capsaicin-sensitive primary afferents by resiniferatoxin (RTX) pretreatment selectively decreased AMV-induced spinal Fos expression, but did not affect AMV-induced antinociception in the formalin test. They suggested that subcutaneous AMV stimulation of the Zusanli point activates central catecholaminergic neurons via capsaicin-insensitive afferent fibers without induction of nociceptive behaviour or by naloxone, a non-selective μ-opioid receptor antagonist, suggesting that there is no participation of an opioid mechanism. Kwon et al. (2001a,b,c) also showed that AMV acupoint stimulation can produce visceral antinociception that is not associated with naloxone-sensitive opioid receptors.

The demonstration of the antinociceptive activity of AMV is in line with the demonstrations that AMV inhibits the nociceptive response induced by acetic acid in mice (Kim et al., 2007). In this study, AMV was injected into specific points of acupuncture. As the doses (0.06 to 6 mg/kg) used by these authors are in the range of those used in the present study, it is suggested that the antinociceptive effect induced by AMV is not related to injection into a specific point of acupuncture, but results from a systemic action.

Motor deficits may create confounds in studies in which antinociception is measured. To clarify if the analgesic effect is not a result of motor deficits, the effects of AMV on rota-rod test was assessed, that is, a classical model for screening central nervous system actions providing information on myorelaxant activity. AMV did not present myorelaxant activity as demonstrated in the rota-rod test that measures grip strength, suggesting that the AMV antinociception observed in this investigation is not exerted through induction of sedation. According to Heneine et al. (2007), AMV lacks analgesic action in test of hot-plate suggesting that its analgesic effect is only peripheral but not central.

It seems that antiinflammatory property of AMV may contribute to its antinociceptive effect. Recent studies have shown that bee venom treatment can induce a significant antiinflammatory response mediated by inhibition of inflammatory mediators, similar to what is achieved with the administration of non-steroidal anti-inflammatory drugs (Miampamba et al., 1992). In experimental rheumatoid arthritis, bee venom treatment significantly decreased the expression of inflammation-related
Table 1. Visceral antinociceptive activity of *Apis mellifera* venom.

<table>
<thead>
<tr>
<th>Group</th>
<th>Dose (mg/kg)</th>
<th>Number of animal constrictions/20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>-</td>
<td>52.16 ± 5.05</td>
</tr>
<tr>
<td>Indomethacin</td>
<td>10</td>
<td>26.00 ± 3.90*</td>
</tr>
<tr>
<td>AMV</td>
<td>0.08</td>
<td>24.67 ± 4.59*</td>
</tr>
<tr>
<td>-</td>
<td>0.8</td>
<td>1.16 ± 0.83***</td>
</tr>
</tbody>
</table>

*p < 0.05 and ***p < 0.001 compared to the vehicle-administered control group (Control).

Table 2. Effect of yohimbine and L-NAME on visceral antinociception induced by of *Apis mellifera* venom.

<table>
<thead>
<tr>
<th>Group</th>
<th>Dose</th>
<th>Number of animal constrictions/20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>-</td>
<td>40.166 ± 3.19</td>
</tr>
<tr>
<td>AMV</td>
<td>0.8</td>
<td>1.54 ± 0.63***</td>
</tr>
<tr>
<td>Yohimbine</td>
<td>2</td>
<td>44.00 ± 4.58</td>
</tr>
<tr>
<td>L-NAME</td>
<td>10</td>
<td>46.66 ± 3.74</td>
</tr>
<tr>
<td>Verapamil</td>
<td>5</td>
<td>46.16 ± 3.10</td>
</tr>
<tr>
<td>Glibenclamide</td>
<td>5</td>
<td>45.66 ± 3.57</td>
</tr>
<tr>
<td>Ruthenium red</td>
<td>3</td>
<td>28.83 ± 8.60</td>
</tr>
<tr>
<td>Naloxone</td>
<td>2</td>
<td>19.40 ± 2.13</td>
</tr>
<tr>
<td>Yohimbine+AMV</td>
<td>2 + 0.8</td>
<td>8.00 ± 3.15***</td>
</tr>
<tr>
<td>L-NAME+AMV</td>
<td>10 + 0.8</td>
<td>4.16 ± 2.22***</td>
</tr>
<tr>
<td>Verapamil+AMV</td>
<td>5 + 0.8</td>
<td>17.56 ± 7.17**</td>
</tr>
<tr>
<td>Glibenclamide+AMV</td>
<td>5 + 0.8</td>
<td>11.33 ± 9.94*</td>
</tr>
<tr>
<td>Ruthenium red+AMV</td>
<td>3 + 0.8</td>
<td>1.83 ± 0.65***</td>
</tr>
<tr>
<td>Naloxone+AMV</td>
<td>2 + 0.8</td>
<td>8.00 ± 3.74**</td>
</tr>
</tbody>
</table>

*p < 0.05 compared to the vehicle-administered control group (Control).

cytokines such as cyclooxygenase-2 (COX-2), phospholipase A2 (PLA2), tumor necrosis factor-α (TNF-α), interleukin (IL)-1, IL-6, nitric oxide (NO) and reactive oxygen species (ROS) (Son et al., 2007) via NF-κB (Kim et al., 2013). It is known that after intraperitoneal administration of acetic acid, inflammatory reactions develop in the peritoneum (Clementi et al., 1999).

According to Know et al. (2005), the soluble fraction (BVF3) contains several small peptides including melittin, apamin, mast cell degranulating (MCD) peptide and minimin. The authors believed that BVAF3-induced antinociception may be produced by the interaction of several constituents of BVAF3 rather than by one specific antinociceptive component.

Conclusion

In conclusion, although AMV efficient diminished the acetic acid-evoked pain-related behaviour, its mechanism is unclear from this study and future studies are needed to verify how the venom exerts its antinociceptive action. Since AMV contains a wide number of constituents, attempts to investigate them individually are slightly challenging, because synergistic interaction among the AMV components may occur.

However, in order to gain better insight into the mechanisms of action of AMV, further efforts, including molecular biology methods, are necessary in the future.

**REFERENCES**


African Journal of Pharmacy and Pharmacology

Related Journals Published by Academic Journals

- Journal of Medicinal Plant Research
- African Journal of Pharmacy and Pharmacology
- Journal of Dentistry and Oral Hygiene
- International Journal of Nursing and Midwifery
- Journal of Parasitology and Vector Biology
- Journal of Pharmacognosy and Phytotherapy
- Journal of Toxicology and Environmental Health Sciences